Business Context and Reporting Period
This Form 8-K filing by Eyenovia, Inc. (trading symbol: EYEN) reports a material definitive agreement entered into on May 7, 2021. The company, incorporated in Delaware and listed on the Nasdaq Capital Market, is an emerging growth company. The filing details a new financing arrangement with Silicon Valley Bank intended to fund working capital and general corporate purposes.
Key Financial Metrics and Agreement Terms
The filing outlines a Loan and Security Agreement with the following financial structure:
- Total Commitment: Up to $25.0 million in term loans.
- Initial Tranche: Up to $7.50 million funded on the closing date (May 7, 2021).
- Future Tranches:
- Up to $7.50 million available through May 31, 2022, subject to commercial sale and performance milestones.
- Up to $10.0 million available through May 31, 2023, subject to commercial sale and performance milestones.
- Interest Rate: The greater of (a) Prime Rate + 1.25% or (b) 5.00%.
- Repayment Terms:
- Interest-only payments through May 31, 2022 (potentially extendable to May 31, 2023 upon milestone achievement).
- 36 equal monthly principal and interest payments thereafter.
- Maturity Date: May 1, 2025.
- Final Payment: A fee equal to 5.00% of the advanced amount, due at maturity or termination.
- Prepayment Fees: 3.0% (first year), 2.0% (second year), or 1.0% (thereafter) of the outstanding principal.
- Security: First lien on substantially all assets; negative pledge on intellectual property.
Equity Component: The company issued warrants to purchase 91,884 shares of common stock at an exercise price of $4.76 per share. The warrants are exercisable for ten years.
Material Changes Versus Prior Period
This filing represents a new material event rather than a periodic financial update. Consequently, there are no comparative revenue, profit, or cash flow metrics provided in this document. The primary material change is the creation of a new direct financial obligation and the issuance of unregistered equity securities (warrants) as of May 7, 2021.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Use of Proceeds: The company intends to use the loan proceeds for working capital and general corporate purposes. Future funding tranches are contingent upon the achievement of a commercial sale and specific performance milestones.
Risks and Covenants:
- Covenants: The agreement includes limitations on additional indebtedness, liens, guaranties, mergers, asset sales, and transactions with affiliates.
- Events of Default: Include non-payment, covenant breaches, insolvency, bankruptcy, or a material adverse effect on the company.
- Consequences of Default: The lender may accelerate payment, increase interest rates, terminate commitments, or perfect security interests.
Unusual Items: The filing notes that certain confidential portions of the Loan and Security Agreement were omitted from the public exhibit.
Investor Verification Checklist
- Verify the current status of the $7.50 million initial tranche and whether funds have been disbursed.
- Monitor the company's progress toward the commercial sale and performance milestones required to access the remaining $17.5 million in funding.
- Review the impact of the 5.00% final payment fee and prepayment penalties on the company's future cash flow flexibility.
- Assess the dilution impact of the 91,884 warrants issued at $4.76 per share.
- Confirm compliance with the negative pledge on intellectual property and other restrictive covenants.